Perturbation of the sarcolemmal membrane in isoproterenol-induced myocardial injury of the rat. Permeability and freeze-fracture studies in vivo and in vitro.

The mechanism whereby cardiotoxic doses of isoproterenol (ISO) induces early permeability alteration of the sarcolemmal membrane is unknown; both beta-receptor overstimulation and direct toxic effect of ISO oxidation products have been implicated. There has been no morphologic observation, furthermore, on the structural basis of permeability alteration during this process. The purpose of the present study was to compare the morphology of cardiocyte injury induced by ISO and oxidized ISO (ISO-O2) and to visualize perturbation of the sarcolemma correlating with the leaky membrane. The authors studied the left ventricular myocardium of rats 10 and 60 minutes after subcutaneous administration of 85 mg/kg ISO and isolated perfused rat hearts exposed for 10 minutes either to ISO or ISO-O2 in a dose of 100 mg/l (10(-4) M) to determine the permeability of the sarcolemmal membrane using the extracellular diffusion tracer horseradish peroxidase (HRP) by light and thin section electron microscopy, the morphology of the sarcolemmal membrane by means of freeze-fracture electron microscopy, and the density of intramembrane particles (IMP) in the sarcolemmal membrane by planimetry using freeze-fracture electron microscopy. In in vivo rat hearts both 10 and 60 minutes after ISO and in vitro (isolated perfused) rat hearts exposed to either ISO or ISO-O2 for 10 minutes, HRP labeled the sarcoplasm of focally located cardiocytes implicating leakiness of the sarcolemmal membrane. HRP positive cardiocytes (with the exception of the in vivo 10 minute group) showed characteristic features of contraction band necrosis (both on light and thin-section electron microscopy) in all groups. Freeze-fracture electron microscopy of sarcolemmal protoplasmic (P) membrane faces revealed two populations of cardiocytes in all groups. P-membrane faces in one population of cardiocytes appeared as in the control. In the other population of cardiocytes, P-membrane faces showed irregular tears. Planimetry demonstrated a significant decrease of IMP numerical densities in P-membrane faces with tears in the in vivo 10 minute group and both with or without tears in the in vivo 60 minutes group and the in vitro groups compared with the control values. Furthermore, with the exception of the 10 minute in vivo group, IMP densities significantly decreased in sarcolemmal membranes with tears compared with those without tears in all experimental groups. These observations are consistent with the view that catecholamine induced myocardial injury is, at least partly, related to the direct toxic effect of catecholamine oxidation products on the sarcolemmal membrane.(ABSTRACT TRUNCATED AT 400 WORDS)     

Linkage map of a region of human chromosome band 11q13 amplified in breast and squamous cell tumors.

DNA amplification involving markers on human chromosome band 11q13 is a consistent feature of several major cancers, notably adenocarcinoma of the breast and squamous cell carcinoma of the head, neck, lung, and esophagus. Since the presence of the amplification may be clinically significant, by defining a subset of patients at increased risk, it is important to establish which of the several genes on the amplified DNA provides the selective force. Here we describe a physical map of the centromeric end of the amplified DNA as it exists in a particular squamous carcinoma cell line (UMSCC2) and establish an unambiguous order for several known markers in the region, including pMS51/D11S97, pHB159/D11S146, BCL1, PRAD1/D11S287, HSTF1/FGF4 and INT2/FGF3. Significantly, PRAD1 is within 120-150 kb of the BCL1 translocation breakpoint and the data identify a new CpG island (D11S814) between PRAD1 and HSTF1. The ordering of the HSTF1 and INT2 genes and the clustering of CpG islands in the region have important implications in assessing whether the frequently observed amplifications at 11q13 are centered on one or more genes.     

Sulfation of L-selectin ligands by an HEV-restricted sulfotransferase regulates lymphocyte homing to lymph nodes

Lymphocytes home to lymph nodes, using L-selectin to bind specific ligands on high endothelial venules (HEV). In vitro studies implicate GlcNAc-6-sulfate as an essential posttranslational modification for ligand activity. Here, we show that genetic deletion of HEC-GlcNAc6ST, a sulfotransferase that is highly restricted to HEV, results in the loss of the binding of recombinant L-selectin to the luminal aspect of HEV, elimination of lymphocyte binding in vitro, and markedly reduced in vivo homing. Reactivity with MECA 79, an adhesion-blocking mAb that stains HEV in lymph nodes and vessels in chronic inflammatory sites, is also lost from the luminal aspects of HEV. These results establish a critical role for HEC-GlcNAc6ST in lymphocyte trafficking and suggest it as an important therapeutic target.     

Glutathione S-transferases and cancer (Review)

Cytosolic glutathione S-transferases are a family of enzymes involved in the metabolism of drugs, toxins, carcinogens and also of anticancer drugs. Recent studies have indicated that glutathione S-transferases (GSTs) may play an important role in the resistance of cells to toxins and carcinogens but also to anticancer drugs. This report reviews the current literature concerning the role of glutathione S-transferases in anticancer drug resistance. Moreover, the significance of GST pi in carcinogenesis and its role as prognostic factor is discussed.     

The Wolff-Parkinson-White syndrome: the cellular substrate for conduction in the accessory atrioventricular pathway

The longstanding quest for the anatomical basis of the Wolff-Parkinson-White syndrome has left many unanswered questions. The ultrastructuralmorphology of the myocytes comprising accessory atrioventricularpathways, which are capable of rapid and variable conduction,is central to understanding the development and behaviour ofthis congenital anomaly, but remains unknown. Examination ofthree surgically resected pathways was performed to determinetheir underlying cellular morphology and the pattern of intercellularcoupling, by correlative light microscopy, electron microscopyand confocal scanning laser microscopy combined with immunohistochemicallocalization of the cardiac gap-junctional protein, connexin43. Two left-sided pathways were composed of myocardium of ‘normalworking ventricular’ type. The right-sided pathway wascomposed almost entirely of highly abnormal myocytes characterizedby aberrant myofibril organisation, with a lack of A-band materialand abnormal mitochondria, but normal intact intercalated disksno different from those seen in left-sided pathways. The gapjunctions of all pathways were composed of connexin43 distributedas in ventricular myocardium, and not as found in atrial oratrioventricular nodal tissues. While myocytes of abnormal structure were present in one ofthe accessory atrioventricular pathways examined, all pathwayshad morphologically normal gap junctions, the structures responsiblefor efficient intercellular coupling, with a pattern of distributionsuggestive of working ventricular myocardium.     

Interactions between the effects of propranolol and nicotine on radial maze performance of rats with lesions of the forebrain cholinergic projection system

This experiment investigated the hypothesis that nicotine-induced regional release of noradrenaline contributes to the improvements in radial maze performance following nicotine treatment in rats with lesions to the forebrain cholinergic projection system (FCPS), by examining whether pretreatment with the noradrenergic beta-receptor antagonist propranolol abolished the facilitative effects of nicotine. After S-AMPA (8.0mM) lesions to the nuclei of origin of the FCPS in the nucleus basalis and medial septal areas, rats displayed long-lasting impairment in long-term reference and short-term working memory in both spatial (place) and associative (cue) radial maze tasks. Performance of control and lesioned rats was assessed after administration of nicotine (0.1mg/kg), propranolol (either 0.5 or 5.0mg/kg) and both treatments. Nicotine reduced working memory error rates in lesioned animals, but did not affect the performance of controls. Propranolol dose-relatedly increased error rates in both control and lesioned animals. Adverse effects were more marked in controls, all four types of error being increased under the high dose of propranolol, whereas in lesioned rats significant increases in error rates above baseline were confined to working memory. The low dose of propranolol, in conjunction with nicotine, abolished the improvement in working memory seen with nicotine alone in lesioned rats. However, under joint treatment with the high dose, the substantial increases in working memory error rates seen in lesioned rats after propranolol alone were reduced to baseline level. In controls, reduction in errors to baseline was seen only in the cue task; place task errors remained significantly elevated. These results suggest that both cholinergic depletion and noradrenergic blockade exert disruptive effects on cognition, but that these effects are largely independent, since an additive or interactive mechanism would be predicted to produce greater disruption, following noradrenergic blockade, in lesioned rather than in control animals. Although facilitative effects of nicotine were abolished with the low dose of propranolol, the results further suggest that these effects are independent of release of noradrenaline, since nicotine continued to reduce errors in control and lesioned animals following blockade of beta receptors with the high dose of propranolol.     

In-vitro schedule-dependency of eo9 and miltefosine in comparison to standard drugs in colon-cancer cells

In vitro screening of new antitumor drugs is often limited to fast chemosensitivity assays. The potency of drugs is studied by measuring growth inhibition at the end of the assay after a fixed drug exposure time. In this study, the human colon cancer cell lines HT29 and SW620, were exposed to drugs for 1 h, 24 h (followed by culture in drug-free medium), 72 h and for 72 h with drug renewal every 24 h. Growth inhibition was evaluated at 48 and 72 h after initial drug addition, using the sulforhodamine B (SRB) assay. Chemosensitivity profiles of the investigational drugs EO9, a bioreductive alkylator, and the ether lipid miltefosine (HPC), were compared to those of drugs with different mechanisms of action: doxorubicin, cisplatin (DDP) and 5-fluorouracil. HPC displayed recovery from growth inhibition, in both cell lines, after drug exposures of 1 and 24 hours. DDP showed an increase for both cell lines (p < 0.05) of growth inhibition when drug was being refreshed every 24 h, compared to 72 h continuous drug exposure. Doxorubicin, 5-fluorouracil and EO9 were more potent in SW620 cells. These data suggest that more initial information can be obtained from drug screening assays, when both continuous and short-term drug exposures are studied, instead of one fixed drug exposure time, and indicates that daily renewal of drugs, may reveal possible drug stability and availability problems.     

Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment

Asparaginase is an effective treatment for patients with acute lymphocytic leukemia (ALL). Unfortunately, asparaginase therapy is associated with a high incidence of hypersensitivity reactions (up to 73%), including life-threatening anaphylaxis, and its half-life of approximately 20 hours necessitates daily administration. Pegaspargase, a modification of L-asparaginase, has a longer half-life (357 hours), a decreased incidence of hypersensitivity reactions, and when doses every 14 days, provides comparable efficacy to asparaginase; however, it is much more expensive per single-dose vial ($980.00 vs $52.38). To determine the pharmacoeconomic impact of the two agents, we conducted a cost-minimization analysis for three common adult ALL protocols. Results showed that pegaspargase was significantly less costly to payers on an inpatient or outpatient basis and warranted addition to our formulary.     

Chromosome 11q13 markers and D-type cyclins in breast cancer

Summary One in six primary human breast cancers has DNA amplification centered on the cyclin D1 gene (CCND1) on chromosome 11q13. This genetic abnormality is preferentially associated with estrogen-receptor positive tumors and may define a sub-class of patients with an adverse prognosis. AlthoughCCND1 has the credentials of a cellular oncogene, being a target for chromosomal translocation and retroviral integration, the 11q13 amplicon encompasses several other markers andCCND1 is not the only candidate for the key gene on the amplified DNA. To assess their relative importance, we have constructed a physical map of the amplified DNA and compared the extent and frequency of amplification across the region. Since it is likely that the gene providing the selective force for amplification will be expressed at elevated levels, we have also examined expression of both RNA and protein. By these criteria, cyclin D1 remains the strongest candidate for the key oncogene on the amplicon and we are currently investigating the functional consequences of its over-expression.Presented by Gordon Peters at the 16th Annual San Antonio Breast Cancer Symposium, San Antonio TX, USA, November 4, 1993; Minisymposium on Molecular Genetics in Breast Cancer.